FDA Brief

Warning letters Drugs

FDA warning letter to

Applied Biological Laboratories Inc.

High riskIssued Mar 24, 2022Posted Mar 28, 2022Center for Drug Evaluation and Research | CDER

FDA warned Applied Biological Laboratories that its Biovanta throat spray and lozenges are unapproved, misbranded drugs promoted for COVID-19.

What happened

FDA reviewed the company’s websites biovanta.com and appliedbioinc.com in February and March 2022, and also reviewed social media pages, and found Biovanta Dual Action Throat Spray and Biovanta Triple Action Lozenges offered for sale with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. FDA says these are unapproved new drugs and misbranded drugs. FTC also reviewed the websites in March 2022 and demanded that the company stop making unsubstantiated COVID-19 claims.

What FDA found

  1. Biovanta Dual Action Throat Spray and Biovanta Triple Action Lozenges are unapproved new drugs because they are intended for COVID-19 and have not been approved by FDA.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded drugs under the FD&C Act.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company introduced or delivered for introduction these products into interstate commerce, which the FD&C Act prohibits for such products.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that Biovanta products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.

What FDA wants

FDA tells the company to immediately stop selling unapproved products for COVID-19, review websites, labels, and promotional materials, and email FDA within 48 hours describing corrective steps. FTC separately requires certification within 48 hours that unsubstantiated claims have stopped.

Who should pay attention

  • retailers and online marketplaces selling Biovanta products
  • companies making COVID-19-related claims for OTC remedies
  • brands using social media influencers or testimonials for health claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk